Is lurbinectedin safe during breastfeeding?
Lurbinectedin (Zepzelca), a chemotherapy drug for small cell lung cancer, lacks specific clinical data on its use during breastfeeding. No studies directly assess transfer into human milk or effects on breastfed infants.[1] Manufacturers and regulators recommend avoiding breastfeeding during treatment and for at least 2 weeks after the final dose to minimize infant exposure.[2][3]
Does lurbinectedin pass into breast milk?
Lurbinectedin is highly protein-bound (>99%) with a large volume of distribution, suggesting low milk penetration, but no direct measurements exist.[1] As an alkylating-like agent, it and its metabolites could theoretically transfer via passive diffusion. Animal data shows distribution into milk in rats, though relevance to humans is unclear.[4] Without human pharmacokinetic studies, risk cannot be quantified.
What effects might it have on a breastfed infant?
Potential infant risks mirror maternal chemotherapy toxicities: bone marrow suppression (anemia, neutropenia, thrombocytopenia), gastrointestinal issues (nausea, diarrhea, fatigue), and elevated liver enzymes.[1][2] Long-term concerns include growth delays or secondary cancers, common with cytotoxic agents. Infants may face higher vulnerability due to immature liver/kidney function and rapid cell division.[5]
How long to pump and dump after treatment?
Guidelines advise no breastfeeding for 2 weeks post-dose, based on lurbinectedin's half-life (∼50 hours) and time for multiple elimination half-lives.[2][3] Lactating patients should discard milk during this period. Consult a lactation specialist or oncologist for individualized timing, considering dose and infant age.
Alternatives for cancer patients who are breastfeeding?
Switch to non-chemo options if feasible, or use formula/suppressed lactation (e.g., cabergoline). Drugs like trastuzumab have more breastfeeding data and lower risks.[5] Patient registries like MotherToBaby provide case reports on similar chemotherapies.
Regulatory and expert guidance
FDA label states: "Advise lactating women not to breastfeed during treatment and for at least 2 weeks after the final dose."[2] LactMed database echoes this, noting insufficient data but high-risk profile due to pharmacology.[3] No patents directly address breastfeeding; see DrugPatentWatch.com for formulation patents expiring 2032–2038.[6]
[1] Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, 2023.
[2] FDA Label: https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/213069s000lbl.pdf
[3] NIH LactMed: https://www.ncbi.nlm.nih.gov/books/NBK501922/
[4] EMA Assessment Report: https://www.ema.europa.eu/en/documents/assessment-report/zepzelca-epar-public-assessment-reporten.pdf
[5] UpToDate: "Breastfeeding and chemotherapy," 2024.
[6] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/ZEPZELCA